8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  December 20, 2017 (December 18, 2017)

CHEMBIO DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter)

Nevada	0-30379	88-0425691
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	3661 Horseblock Road
	Medford, NY 11763
	(Address of principal executive offices)
	631-924-1135
	(Registrant's Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Item 1.01.Entry into a Material Definitive Agreement.

As of December 18, 2017, Chembio Diagnostics, Inc. (the "Company") entered into an employment agreement (the "Employment Agreement") with Neil A. Goldman to serve as Executive Vice President and Chief Financial Officer of the Company.  This Employment Agreement is described in Item 5.02(c) below, which description is incorporated by reference into this Item 1.01.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) As of December 18, 2017 (the "Effective Date"), the Company entered into an Employment Agreement with Neil A. Goldman to serve as the Company's Executive Vice President and Chief Financial Officer.  Under the Employment Agreement, the Company will pay Mr. Goldman an annual base salary of $300,000, with the possibility of a discretionary, performance-based annual cash bonus of up to 40% of his base salary. 

In the event Mr. Goldman's employment is terminated by reason of disability or for "cause," as defined in the Employment Agreement, or due to Mr. Goldman's resignation or voluntary termination, all compensation, including his base salary, his right to receive a performance bonus, and benefits, and the vesting of any unvested options, will cease as of his termination date, and Mr. Goldman will receive no severance benefits. 

If the Company terminates Mr. Goldman's employment without cause or Mr. Goldman terminates his employment for a reasonable basis, as defined in the Employment Agreement (which includes involuntary termination within a six-month period upon a "Change of Control"), then the Company will pay Mr. Goldman his base salary for a period of twelve months and the Company's monthly share of health insurance premiums as severance.

The Employment Agreement also contains provisions prohibiting Mr. Goldman from (i) soliciting the Company's employees for a period of twenty-four months following his termination, (ii) soliciting the Company's customers, agents, or other sources of distribution of the Company's business for a period of twelve months following his termination, and (iii) except where termination is involuntary upon a "Change in Control", for a period of twelve months following termination of the Employment Agreement (or for a period of six months after termination if Mr. Goldman is not entitled to severance under the Employment Agreement), engaging or participating in any business that directly competes with the business activities of the Company in any market in which the Company is in business or plans to do business. 

The Employment Agreement, which is for a term of one year, also provides that as of December 18, 2017, the Company's Board Of Directors grant Mr. Goldman stock options, pursuant to the Company's 2014 Stock Incentive Plan (the "Plan"), to purchase 125,000 shares of the Company's common stock, with the exercise price equal to the volume weighted average traded price of the Company's common stock on Nasdaq on December 18, 2017, and with options to purchase (i) 41,666 shares to be exercisable on December 18, 2018, (ii) 41,667 shares to be exercisable on December 18, 2019, and (iii) 41,667 shares to be exercisable on December 18, 2020.   That portion of the stock options granted to Mr. Goldman that become exercisable in any given year with an aggregate exercise price of up to, but not more than, $100,000 shall be incentive stock options under the Plan, and within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, and any other stock options that become exercisable in that year shall be non-qualified stock options under the Plan.  If not exercised sooner, the stock options expire on December 18, 2024.

The foregoing description of the Employment Agreement is qualified in its entirety by the full text of the Employment Agreement.

Prior to joining the Company, Mr. Goldman worked at J.S. Held LLC, a private equity-sponsored national consulting firm to insurance carriers and law firms.  At J.S. Held, Mr. Goldman served as Executive Vice President - Corporate Development and CFO from 2015 to 2017, during which time he successfully completed six acquisitions and drove significant sales and EBITDA growth.  From 2005 to 2015, Mr. Goldman held senior level positions at Unwired Technology LLC and then Delphi Corp., now Aptiv plc (NYSE: APTV), following Delphi's acquisition of Unwired in 2014. Unwired was a hi-tech, tier-1 automotive OEM/consumer electronics manufacturer and portfolio company of American Capital.  Mr. Goldman's positions at Unwired included Executive Vice President-Corporate Development and CFO, and Senior Vice President-Chief Operating & Financial Officer. At Delphi, Mr. Goldman served as Global Finance Director for the Delphi Data Connectivity division.  In these roles, Mr. Goldman led the successful sale of Unwired to Delphi, delivering a significant return on investment to shareholders, drove substantial sales growth, and managed global manufacturing, planning, purchasing, inventory and logistics, in addition to customary finance areas.  Prior to Unwired, Mr. Goldman served as CFO of EPPCO Enterprises from 2003 to 2005 and worked from 1989 to 2002 at Ernst & Young and Cap Gemini Ernst & Young following the latter's acquisition of Ernst & Young's consulting business. At Ernst & Young, Mr. Goldman was an auditor, primarily of Fortune 500 companies, and advanced into regional and national management consulting positions.  Mr. Goldman received a B.S. in Business-Accountancy from Miami University, Oxford, OH. 

(b) On December 18, 2017, Richard J. Larkin retired as Executive Vice President and Chief Financial Officer of the Company and its subsidiaries. It is anticipated that Mr. Larkin will be a part-time consultant with the Company for a period to be determined.

On August 11, 2017, Mr. Larkin informed the Company of his intention to retire as Executive Vice President and Chief Financial Officer of the Company and its subsidiaries at the earlier to occur of December 31, 2017 or the date on which a new CFO has been engaged and commences working for the Company. This was reported in a Form 8-K at the time.

ITEM 9.01.Financial Statements and Exhibits

Exhibits.

99.1 Press Release entitled "Chembio Announces Appointment of Neil A. Goldman as Chief Financial Officer" dated December 20, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  December 20, 2017Chembio Diagnostics, Inc.

By:  

John J. Sperzel, III

Chief Executive Officer

EXHIBIT INDEX

Exhibit NumberDescription

99.1 Press Release entitled "Chembio Announces Appointment of Neil A. Goldman as Chief Financial Officer" dated December 20, 2017.

EX-99.1

Chembio Diagnostics Announces Appointment of Neil A. Goldman as

Chief Financial Officer

MEDFORD, N.Y., December 20, 2017 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the appointment of Neil A. Goldman, CPA, as Chembio's Executive Vice President and Chief Financial Officer (CFO) commencing December 18, 2017.  Mr. Goldman, who will be based at the Company's headquarters in Medford, NY, comes to Chembio with 28 years of industry experience spanning public accounting, strategic transactions, corporate development and management of financial operations for multiple manufacturing organizations operating domestically and internationally.  Mr. Goldman succeeds Richard J. Larkin, who has served as Chembio's Executive Vice President and Chief Financial Officer since 2003.  Mr. Larkin announced his intent to retire in August 2017.

John Sperzel, Chembio's Chief Executive Officer, commented, "We are very pleased to welcome Neil to Chembio.  Neil has an impressive track record of success, managing a range of executive functions for several global manufacturing companies.  As we are actively expanding our global commercialization and manufacturing business, his expertise with international sales and transactions, finance, and manufacturing/operations makes Neil an ideal addition to Chembio's executive management team."

Mr. Sperzel continued, "All of us at Chembio are thankful to Rich Larkin for his years of service and dedication.  For fourteen years, Rich has been a key member of our management team and we are grateful for his many important contributions.  We wish Rich well in his retirement."

Mr. Goldman comes to Chembio from J.S. Held LLC, a private equity-sponsored national consulting firm to insurance carriers and law firms.  At J.S. Held, Mr. Goldman served as Executive Vice President-Corporate Development and CFO from 2015 to 2017, during which time he successfully completed six acquisitions and drove significant sales and EBITDA growth.  From 2005 to 2015, Mr. Goldman held senior level positions at Unwired Technology LLC and then Delphi Corp., now Aptiv plc (NYSE: APTV), following Delphi's acquisition of Unwired in 2014. Unwired was a hi-tech, tier-1 automotive OEM/consumer electronics manufacturer and portfolio company of American Capital.  Mr. Goldman's positions at Unwired included Executive Vice President-Corporate Development and CFO, and Senior Vice President-Chief Operating & Financial Officer. At Delphi, Mr. Goldman served as Global Finance Director for the Delphi Data Connectivity division.  In these roles, Mr. Goldman led the successful sale of Unwired to Delphi, delivering a significant return on investment to shareholders, drove substantial sales growth, and managed global manufacturing, planning, purchasing, inventory and logistics, in addition to customary finance areas.

Prior to Unwired, Mr. Goldman served as CFO of EPPCO Enterprises from 2003 to 2005, and worked from 1989 to 2002 at Ernst & Young and Cap Gemini Ernst & Young following the latter's acquisition of Ernst & Young's consulting business. At Ernst & Young, Mr. Goldman was an auditor primarily of Fortune 500 companies and advanced into regional and national management consulting positions.  Mr. Goldman received a B.S. in Business-Accountancy from Miami University, Oxford, OH.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets rapid diagnostic tests in the growing $8.0 billion POC testing market. The Company markets its products directly and through third-party distributorsunder the brand names: DPP^®, STAT-PAK^®, SURE CHECK^®, and STAT-VIEW^®.

Chembio has developed and patented the DPP^®technology platform, which offers significant advantages over traditional POC lateral-flow technologies and provides the Company with a significant pipeline of business opportunities in the area of sexually transmitted disease, tropical and fever disease, and technology collaborations.

Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Each of Chembio Diagnostic Systems Inc. and Chembio Diagnostics Malaysia Sdn Bhd is a wholly-owned subsidiary of Chembio Diagnostics, Inc.  For more information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended.  Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management.  Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties.  Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products.  Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.  Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact: 

Vida Strategic Partners (investor relations)

Stephanie C. Diaz

(415) 675-7401

sdiaz@vidasp.com